RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Symbol
RAPT on Nasdaq
Shares outstanding
27,748,559
Price per share
$57.61
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
27,200,695
Total reported value
$921,288,979
% of total 13F portfolios
0.01%
Share change
+13,577,455
Value change
+$461,871,577
Number of holders
99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ForGrowth III PA B.V. 7.4% $47,291,008 1,833,333 ForGrowth III PA B.V. 23 Oct 2025
Redmile Group, LLC 9.9% $14,934,463 1,765,303 Redmile Group, LLC 30 Jun 2025
RTW INVESTMENTS, LP 5.9% $55,041,487 1,637,165 RTW Investments, LP 31 Dec 2025
VANGUARD GROUP INC 4.2% $17,958,239 696,188 The Vanguard Group 30 Sep 2025
Nantahala Capital Management, LLC 3.8% -33% $16,074,692 -$8,467,788 623,282 -35% Nantahala Capital Management, LLC 30 Sep 2025
Deep Track Capital, LP 0.4% $3,713,262 110,448 Deep Track Capital, LP 31 Dec 2025

As of 31 Dec 2025, 99 institutional investors reported holding 27,200,695 shares of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT). This represents 98% of the company’s total 27,748,559 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TCG Crossover Management, LLC 9.3% 2,582,408 +58% 2.9% $87,466,159
FCPM III SERVICES B.V. 6.6% 1,833,333 +433% 8.1% $62,094,989
ORBIMED ADVISORS LLC 5.9% 1,642,891 +51% 1.2% $55,644,718
RTW INVESTMENTS, LP 5.9% 1,637,165 +11% 0.56% $55,450,779
Foresite Capital Management VI LLC 5.6% 1,562,500 0% 16% $52,921,875
Siren, L.L.C. 5% 1,375,000 +137% 1.4% $46,571,250
VANGUARD GROUP INC 4.3% 1,186,791 +70% 0% $40,196,611
Frazier Life Sciences Management, L.P. 3.5% 983,333 0.89% $33,305,489
BRAIDWELL LP 3.4% 929,694 1% $31,488,736
Redmile Group, LLC 3.2% 885,927 +60% 2.2% $30,006,347
PERCEPTIVE ADVISORS LLC 3% 825,890 +349% 0.51% $27,972,894
Soleus Capital Management, L.P. 2.8% 764,000 +42% 1.1% $25,876,680
Nantahala Capital Management, LLC 2.7% 754,153 +21% 1.5% $25,543,162
Ikarian Capital, LLC 2.4% 665,271 +8.2% 2.9% $22,532,728
Caligan Partners LP 2.3% 644,400 2% $21,825,828
STATE STREET CORP 2.3% 639,804 +1611% 0% $21,670,161
CITADEL ADVISORS LLC 2.1% 591,802 +3711% 0.01% $20,044,334
GREAT POINT PARTNERS LLC 2.1% 581,187 6.4% $19,684,804
Octagon Capital Advisors LP 2.1% 574,000 2.4% $19,441,380
ADAR1 Capital Management, LLC 1.8% 509,679 +0.38% 1.3% $17,262,828
BlackRock, Inc. 1.8% 486,153 +443% 0% $16,466,002
BOONE CAPITAL MANAGEMENT LLC 1.7% 470,456 -40% 5% $15,934,345
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.5% 424,862 +836% 0.02% $14,390,076
MPM BIOIMPACT LLC 1.4% 397,906 1.5% $13,477,076
BOOTHBAY FUND MANAGEMENT, LLC 1.4% 390,747 +75% 0.35% $13,234,601

Institutional Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 27,200,695 $921,288,979 +$461,871,577 $33.87 99
2025 Q3 13,622,837 $351,333,277 +$19,238,054 $25.79 60
2025 Q2 15,619,662 $124,884,006 +$124,882,925 $8.00 45